We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Dual Path Platform Assay Evaluated for Leptospirosis

By LabMedica International staff writers
Posted on 08 Mar 2018
Print article
Image: Representative non-reactive (A), strongly reactive (B) and weakly reactive (C) Dual Path Platform (DPP) assay results for leptospirosis (Photo courtesy of the Oswaldo Cruz Foundation).
Image: Representative non-reactive (A), strongly reactive (B) and weakly reactive (C) Dual Path Platform (DPP) assay results for leptospirosis (Photo courtesy of the Oswaldo Cruz Foundation).
Leptospirosis is an important global cause of acute fever and a leading cause of morbidity among zoonotic diseases and annually, more than one million cases and 50,000 deaths occur worldwide. Approximately 5% to10% of symptomatic patients develop severe manifestations, including multi-system dysfunction and 15% of these may die.

The gold standards for diagnosing leptospirosis, the microscopic agglutination test (MAT) and hemoculture, have limitations. MAT requires maintenance of reference Leptospira cultures and paired sera for diagnosis, and blood cultures are generally low yield. Early detection of leptospirosis with field-ready diagnostics may improve clinical management and mitigate outbreaks.

Scientists from the Oswaldo Cruz Foundation (Salvador, Brazil; www.bahia.fiocruz.br) and their colleagues sequentially enrolled 98 patients hospitalized for acute febrile illnesses, of which they confirmed 32 by leptospirosis reference tests. The patients were from a reference infectious diseases hospital and the specimens were collected from April 18 to October 18, 2012. The study compares the diagnostic accuracy and clinical utility of the point-of-care Dual Path Platform (DPP) using finger stick blood (FSB) against the serum DPP, venous whole blood (VWB) DPP, immunoglobulin-M enzyme-linked immunosorbent assay (IgM-ELISA), and clinical impression.

The DPP (Chembio Diagnostic Systems, Medford, New York, USA; www.chembio.com) utilizes a variation of lateral flow technology, whereby the biological sample and the colorimetric marker are separately delivered on perpendicular nitrocellulose membranes. The team found that DPP sensitivity for classic leptospirosis was 93% by FSB and 96% by VWB. Both POC assays were more sensitive than serum DPP (85%) and serum IgM-ELISA (81%), and similar to clinical impression (96%). The FSB and the VWB DPP detected 40% (2 of 5) and 80% (4 of 5) of the confirmed leptospiral meningitis, respectively, none of which clinicians suspected to be leptospirosis at triage. DPP specificity for classic leptospirosis was 80% by FSB and 75% by VWB.

The authors concluded that the FSB DPP is a rapid, portable alternative to laboratory-based diagnostics for the detection of severe leptospirosis. It expands the diagnostic landscape for effective clinical and outbreak management, and may improve detection of leptospirosis cases presenting with meningitis. The study was published on February 20, 2018, in the journal Public Library of Science Neglected Tropical Diseases.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.